CY1122760T1 - Τροποποιητης εξενατιδης και χρηση αυτου - Google Patents
Τροποποιητης εξενατιδης και χρηση αυτουInfo
- Publication number
- CY1122760T1 CY1122760T1 CY20201100184T CY201100184T CY1122760T1 CY 1122760 T1 CY1122760 T1 CY 1122760T1 CY 20201100184 T CY20201100184 T CY 20201100184T CY 201100184 T CY201100184 T CY 201100184T CY 1122760 T1 CY1122760 T1 CY 1122760T1
- Authority
- CY
- Cyprus
- Prior art keywords
- manufacture
- drugs
- exenatide
- diseases
- medicaments
- Prior art date
Links
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 title abstract 3
- 108010011459 Exenatide Proteins 0.000 title abstract 3
- 229960001519 exenatide Drugs 0.000 title abstract 3
- 239000003607 modifier Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 6
- 239000003814 drug Substances 0.000 abstract 5
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 208000024891 symptom Diseases 0.000 abstract 2
- 208000004930 Fatty Liver Diseases 0.000 abstract 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 1
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 239000000883 anti-obesity agent Substances 0.000 abstract 1
- 230000023852 carbohydrate metabolic process Effects 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Αποκαλύπτονται ένας τροποποιητής εξενατίδης για τη σύνδεση της εξενατίδης σε μια λιπαρή αλυσίδα με ένα καρβοξυ στο άκρο αυτής μέσω ενός υδρόφιλου συνδετικού βραχίονα, και μια χρήση αυτού στην παρασκευή φαρμάκων που χρησιμεύουν ως αγωνιστής υποδοχέα GLΡ-1• μια χρήση στην παρασκευή φαρμάκων για την πρόληψη ή/και θεραπευτική αγωγή ασθενειών ή/και συμπτωμάτων που σχετίζονται με χαμηλή δραστικότητα υποδοχέα GLΡ-1• μια χρήση στην παρασκευή φαρμάκων για ασθένειες ή/και συμπτώματα που σχετίζονται με γλυκομεταβολισμό• μια χρήση στην παρασκευή φαρμάκων για διαβήτη• μια χρήση στην παρασκευή φαρμάκων για ασθένεια λιπώδους ήπατος, και χρήση στην παρασκευή φαρμάκων για απώλεια βάρους.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510619012.7A CN106554403B (zh) | 2015-09-25 | 2015-09-25 | 艾塞那肽修饰物及其用途 |
| PCT/CN2016/098844 WO2017050157A1 (zh) | 2015-09-25 | 2016-09-13 | 艾塞那肽修饰物及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122760T1 true CY1122760T1 (el) | 2021-03-12 |
Family
ID=58385848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100184T CY1122760T1 (el) | 2015-09-25 | 2020-02-28 | Τροποποιητης εξενατιδης και χρηση αυτου |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11179467B2 (el) |
| EP (1) | EP3321279B1 (el) |
| JP (1) | JP6647387B2 (el) |
| KR (1) | KR102005294B1 (el) |
| CN (1) | CN106554403B (el) |
| AU (1) | AU2016328015B9 (el) |
| CA (1) | CA2995613C (el) |
| CY (1) | CY1122760T1 (el) |
| DK (1) | DK3321279T3 (el) |
| ES (1) | ES2775185T3 (el) |
| HR (1) | HRP20200332T1 (el) |
| HU (1) | HUE048411T2 (el) |
| LT (1) | LT3321279T (el) |
| PL (1) | PL3321279T3 (el) |
| PT (1) | PT3321279T (el) |
| RS (1) | RS60053B1 (el) |
| SI (1) | SI3321279T1 (el) |
| SM (1) | SMT202000117T1 (el) |
| WO (1) | WO2017050157A1 (el) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111333714A (zh) * | 2020-03-05 | 2020-06-26 | 成都奥达生物科技有限公司 | 一种长效glp-1化合物 |
| CN112939771A (zh) * | 2021-01-28 | 2021-06-11 | 宁夏蓝博思化学技术有限公司 | 长链烷基二酸单叔丁酯的制备方法 |
| US12215133B2 (en) | 2021-03-25 | 2025-02-04 | Brightgene Bio-Medical Technology Co., Ltd. | GIP and GLP-1 dual receptor agonist, pharmaceutical composition, and use |
| CN117222661A (zh) * | 2021-03-25 | 2023-12-12 | 博瑞生物医药（苏州）股份有限公司 | Gip和glp-1的双受体激动剂、药物组合物及用途 |
| WO2024061310A1 (zh) * | 2022-09-23 | 2024-03-28 | 博瑞生物医药（苏州）股份有限公司 | 一种glp-1和gip双受体激动剂药物组合物及其用途 |
| CN117736118B (zh) * | 2023-12-15 | 2024-10-18 | 四川普康药业有限公司 | Fmoc-AEEA的合成方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1056775B1 (en) | 1998-02-27 | 2010-04-28 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
| EP1609478A1 (en) | 1999-01-14 | 2005-12-28 | Amylin Pharmaceuticals, Inc. | Exendin agonist peptide formulations |
| EP1667724A2 (en) | 2003-09-19 | 2006-06-14 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| KR20070120112A (ko) * | 2005-03-18 | 2007-12-21 | 노보 노르디스크 에이/에스 | 연장형 ｇｌｐ-1 화합물 |
| TWI372629B (en) * | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| CN102827284B (zh) | 2006-11-14 | 2015-07-29 | 上海仁会生物制药股份有限公司 | 带有聚乙二醇基团的Exendin或其类似物及其制剂和用途 |
| CN101215324B (zh) | 2007-12-26 | 2010-11-24 | 吉林大学 | 艾塞那肽短肽模拟肽及其在制备糖尿病治疗药物中的应用 |
| BRPI0906643A2 (pt) * | 2008-02-01 | 2019-09-10 | Ascendis Pharma As | profármaco compreendendo um conjugado fármaco-ligante |
| EP2337585A1 (en) * | 2008-09-19 | 2011-06-29 | Nektar Therapeutics | Polymer conjugates of glp-2-like peptides |
| CN101870728A (zh) | 2009-04-23 | 2010-10-27 | 派格生物医药(苏州)有限公司 | 新型Exendin变体及其缀合物 |
| CN102397558B (zh) | 2010-09-09 | 2013-08-14 | 中国人民解放军军事医学科学院毒物药物研究所 | Exendin-4类似物的定位聚乙二醇化修饰物及其用途 |
| EP2438930A1 (en) | 2010-09-17 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Prodrugs comprising an exendin linker conjugate |
| US20140256626A1 (en) | 2011-10-18 | 2014-09-11 | Prolynx Llc | Peg conjugates of exenatide |
| CN102532303A (zh) | 2011-12-22 | 2012-07-04 | 江苏弘和药物研发有限公司 | 聚乙二醇缀合的艾塞那肽的合成及应用 |
| CN102827270A (zh) | 2012-09-13 | 2012-12-19 | 无锡和邦生物科技有限公司 | 一种聚乙二醇化艾塞那肽衍生物及其用途 |
| CN103405753B (zh) * | 2013-08-13 | 2016-05-11 | 上海仁会生物制药股份有限公司 | 稳定的促胰岛素分泌肽水针药物组合物 |
| KR101768446B1 (ko) * | 2014-03-21 | 2017-08-17 | 애니젠 주식회사 | 신규한 엑세나타이드 유사체 및 그의 용도 |
-
2015
- 2015-09-25 CN CN201510619012.7A patent/CN106554403B/zh active Active
-
2016
- 2016-09-13 CA CA2995613A patent/CA2995613C/en active Active
- 2016-09-13 PL PL16848039T patent/PL3321279T3/pl unknown
- 2016-09-13 ES ES16848039T patent/ES2775185T3/es active Active
- 2016-09-13 HU HUE16848039A patent/HUE048411T2/hu unknown
- 2016-09-13 EP EP16848039.0A patent/EP3321279B1/en active Active
- 2016-09-13 PT PT168480390T patent/PT3321279T/pt unknown
- 2016-09-13 SI SI201630653T patent/SI3321279T1/sl unknown
- 2016-09-13 RS RS20200228A patent/RS60053B1/sr unknown
- 2016-09-13 DK DK16848039.0T patent/DK3321279T3/da active
- 2016-09-13 AU AU2016328015A patent/AU2016328015B9/en active Active
- 2016-09-13 LT LTEP16848039.0T patent/LT3321279T/lt unknown
- 2016-09-13 SM SM20200117T patent/SMT202000117T1/it unknown
- 2016-09-13 JP JP2018506893A patent/JP6647387B2/ja active Active
- 2016-09-13 KR KR1020187005100A patent/KR102005294B1/ko active Active
- 2016-09-13 WO PCT/CN2016/098844 patent/WO2017050157A1/zh active Application Filing
- 2016-09-13 US US15/752,838 patent/US11179467B2/en active Active
-
2020
- 2020-02-27 HR HRP20200332TT patent/HRP20200332T1/hr unknown
- 2020-02-28 CY CY20201100184T patent/CY1122760T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT3321279T (lt) | 2020-04-10 |
| ES2775185T3 (es) | 2020-07-24 |
| HUE048411T2 (hu) | 2020-07-28 |
| PT3321279T (pt) | 2020-03-05 |
| KR102005294B1 (ko) | 2019-07-30 |
| CN106554403B (zh) | 2021-08-31 |
| WO2017050157A1 (zh) | 2017-03-30 |
| AU2016328015A9 (en) | 2018-11-01 |
| EP3321279B1 (en) | 2020-02-12 |
| JP2018531217A (ja) | 2018-10-25 |
| AU2016328015A1 (en) | 2018-03-01 |
| KR20180031740A (ko) | 2018-03-28 |
| AU2016328015B2 (en) | 2018-10-25 |
| HRP20200332T1 (hr) | 2020-06-12 |
| DK3321279T3 (da) | 2020-03-09 |
| US11179467B2 (en) | 2021-11-23 |
| AU2016328015B9 (en) | 2018-12-06 |
| RS60053B1 (sr) | 2020-04-30 |
| CN106554403A (zh) | 2017-04-05 |
| JP6647387B2 (ja) | 2020-02-14 |
| EP3321279A4 (en) | 2018-05-16 |
| EP3321279A1 (en) | 2018-05-16 |
| CA2995613A1 (en) | 2017-03-30 |
| CA2995613C (en) | 2021-07-20 |
| SMT202000117T1 (it) | 2020-03-13 |
| PL3321279T3 (pl) | 2020-10-19 |
| US20200101162A1 (en) | 2020-04-02 |
| SI3321279T1 (sl) | 2020-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122760T1 (el) | Τροποποιητης εξενατιδης και χρηση αυτου | |
| CY1125495T1 (el) | Φαρμακευτικη συνθεση αποτελουμενη αποτιβοζανιμπη | |
| UY37505A (es) | Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico | |
| CY1122466T1 (el) | Σκευασμα αντισωματος αντι il-17ra και θεραπευτικα σχηματα για την αγωγη της ψωριασης | |
| CY1120030T1 (el) | Διπλοι glp1/gip ή τριγωνικοι αγωνιστες glp1/gip/ γλυκαγονης | |
| CY1125068T1 (el) | Ενωσεις τετραϋποκατεστημενου αλκενιου και χρηση αυτων | |
| CY1121203T1 (el) | Θεραπευτικες χρησεις της εμπαγλιφλοζινης | |
| CY1121462T1 (el) | Ακυλιωμενα αναλογα γλυκαγονης | |
| BR112018073511A2 (pt) | polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos | |
| CY1125326T1 (el) | Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων. | |
| CY1123485T1 (el) | Συνθεσεις και μεθοδοι για τη θεραπεια νοσων | |
| CY1119577T1 (el) | Συν-αγωνιστες υποδοχεα γλυκαγονης/glp-1 | |
| Zhan et al. | Toxins and derivatives in molecular pharmaceutics: drug delivery and targeted therapy | |
| EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
| MX2017014822A (es) | Composiciones y métodos para la reprogramación del tcr con proteínas de fusión. | |
| BR112016022465A2 (pt) | agonistas de receptores de glp-1/glucagon duplo peptídicos derivados de exendina-4 | |
| MX375639B (es) | Derivados de heterociclilos sustituidos como inhibidores de cdk | |
| BR112015025464A2 (pt) | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico | |
| CL2012000092A1 (es) | Compuestos derivados de piridina y pirazina o una sal de los mismos, moduladores de proteina quinasa cdk9; composicion farmaceutica que los comprende, util para el tratamiento del cancer, hipotrofia cardiaca, vih y enfermedades inflamatorias. | |
| BR112017009807A2 (pt) | métodos e formulações para tratamento de doenças oculares vasculares | |
| BR112015031903A2 (pt) | composto, sal farmaceuticamente aceitável do composto, composição farmacêutica e utilização de um composto | |
| BR112016022754A2 (pt) | derivados de exendina-4 como agonistas peptídicos duplos dos receptores de glp-1 / glucagon | |
| DOP2013000280A (es) | Proteínas de unión a antígeno | |
| MX2015015228A (es) | Sobetirome en el tratamiento de enfermedades de mielinizacion. | |
| BR112016011789A2 (pt) | Derivados de purina, composição farmacêutica compreendendo os mesmos e uso dos mesmos |